Quality of life and adjuvant tamoxifen treatment in breast cancer patients: Original article

European Journal of Cancer Care

Volumn 18, Issue 5, 2009, Pages 500-506

  Boehm, D U ^a   Lebrecht, A ^a   Eckhardt, T ^b   Albrich, S ^a   Schmidt, M ^a   Siggelkow, W ^a   Kandelhardt, E ^b   Koelbl, H ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Breast cancer; Quality of life; Side effects; Tamoxifen

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; TAMOXIFEN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BODY IMAGE; BREAST TUMOR; FEMALE; HUMAN; METHODOLOGY; MIDDLE AGED; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; QUESTIONNAIRE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BODY IMAGE; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; TAMOXIFEN;

EID: 69149095481     PISSN: 09615423     EISSN: 13652354     Source Type: Journal    
DOI: 10.1111/j.1365-2354.2008.01015.x     Document Type: Article

References (36)

1. Aaronson N.K., Ahmedzai S., Bergman B., Bullinger M., Cull A., Duez N.J., Filiberti A., Flechtner H., Fleishman S.B. De Haes J.C. (1993) The European organization for research and treatment of cancer QLQ-c30: a quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute 85, 365 376.
2. Bergman L., Beelen M.L., Gallee M.P., Hollema H., Benraadt J. Van Leeuwen F.E. (2000) Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of liver and endometrial cancer risk following tamoxifen. Lancet 356, 881 887.
3. Cella D., Fallowfield L., Barker P., Cuzick J., Locker G. Howell A. (2006) Quality of life of postmenopausal women in the ATAC ('Arimidex', tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer. Breast Cancer Research and Treatment 100, 273 284. (Pubitemid 44707921)
4. Day R., Ganz P.A., Costantino J.P., Cronin W.M., Wickerham D.L. Fisher B. (1999) Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. Journal of Clinical Oncology 17, 2659 2669.
5. Dow K.H., Ferrell B.R., Leigh S., Ly J. Gulasekaram P. (1996) An evaluation of the quality of life among long-term survivors of breast cancer. Breast Cancer Research and Treatment 39, 261 273.
6. Early Breast Cancer Trialists' Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Lancet 339, 71 85.
7. Early Breast Cancer Trialists' Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351, 1451 1467.
8. Fallowfield L., Fleissig A., Edwards R., West A., Powles T.J., Howell A. Cuzick J. (2001) Tamoxifen for the prevention of breast cancer: psychosocial impact on women participating in two randomized controlled trials. Journal of Clinical Oncology 19, 1885 1892.
9. Fallowfield L., Cella D., Cuzick J., Francis S., Locker G. Howell A. (2004a) Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. Journal of Clinical Oncology 22, 4261 4271.
10. Fallowfield L., Mcgurk R. Dixon M. (2004b) Same gain, less pain: potential patient preferences for adjuvant treatment in premenopausal women with early breast cancer. European Journal of Cancer 40, 2403 2410.
11. Fallowfield L.J. (2004) Evolution of breast cancer treatments: current options and quality-of-life considerations. European Journal of Oncology Nursing 8 (Suppl. 2 S75 S82.
12. Fallowfield L.J., Leaity S.K., Howell A., Benson S. Cella D. (1999) Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B. Breast Cancer Research and Treatment 55, 189 199.
13. Fallowfield L.J., Bliss J.M., Porter L.S., Price M.H., Snowdon C.F., Jones S.E., Coombes R.C. Hall E. (2006) Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. Journal of Clinical Oncology 24, 910 917.
14. Ferrell B.R., Dow K.H. Grant M. (1995) Measurement of the quality of life in cancer survivors. Quality of Life Research 4, 523 531.
15. Fisher B., Costantino J., Redmond C., Poisson R., Bowman D., Couture J., Dimitrov N.V., Wolmark N., Wickerham D.L., Fisher E.R. (1989) A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. New England Journal of Medicine 320, 479 484. (Pubitemid 19062522)
16. Fisher B., Dignam J., Bryant J., Decillis A., Wickerham D.L., Wolmark N., Costantino J., Redmond C., Fisher E.R., Bowman D.M., Deschenes L., Dimitrov N.V., Margolese R.G., Robidoux A., Shibata H., Terz J., Paterson A.H., Feldman M.I., Farrar W., Evans J. Lickley H.L. (1996) Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. Journal of the National Cancer Institute 88, 1529 1542.
17. Fisher B., Dignam J., Bryant J. Wolmark N. (2001) Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. Journal of the National Cancer Institute 93, 684 690.
18. Ganz P.A. (2001) Impact of tamoxifen adjuvant therapy on symptoms, functioning, and quality of life. Journal of the National Cancer Institute. Monographs 30, 130 134.
19. Ganz P.A., Coscarelli A., Fred C., Kahn B., Polinsky M.L. Petersen L. (1996) Breast cancer survivors: psychosocial concerns and quality of life. Breast Cancer Research and Treatment 38, 183 199.
20. Ganz P.A., Rowland J.H., Meyerowitz B.E. Desmond K.A. (1998) Impact of different adjuvant therapy strategies on quality of life in breast cancer survivors. Recent Results in Cancer Research 152, 396 411.
21. Ganz P.A., Desmond K.A., Belin T.R., Meyerowitz B.E. Rowland J.H. (1999) Predictors of sexual health in women after a breast cancer diagnosis. Journal of Clinical Oncology 17, 2371 2380.
22. Ganz P.A., Desmond K.A., Leedham B., Rowland J.H., Meyerowitz B.E. Belin T.R. (2002) Quality of life in long-term, disease-free survivors of breast cancer: a follow-up study. Journal of the National Cancer Institute 94, 39 49.
23. Goodwin P.J., Black J.T., Bordeleau L.J. Ganz P.A. (2003) Health-related quality-of-life measurement in randomized clinical trials in breast cancer-taking stock. Journal of the National Cancer Institute 95, 263 281.
24. Goss P.E., Ingle J.N., Martino S., Robert N.J., Muss H.B., Piccart M.J., Castiglione M., Tu D., Shepherd L.E., Pritchard K.I., Livingston R.B., Davidson N.E., Norton L., Perez E.A., Abrams J.S., Cameron D.A., Palmer M.J. Pater J.L. (2005) Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. Journal of the National Cancer Institute 97, 1262 1271.
25. Howell A., Cuzick J., Baum M., Buzdar A., Dowsett M., Forbes J.F., Hoctin-Boes G., Houghton J., Locker G.Y. Tobias J.S. (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365, 60 62.
26. Jakesz R., Jonat W., Gnant M., Mittlboeck M., Greil R., Tausch C., Hilfrich J., Kwasny W., Menzel C., Samonigg H., Seifert M., Gademann G., Kaufmann M. Wolfgang J. (2005) Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366, 455 462.
27. Kristensen B., Ejlertsen B., Dalgaard P., Larsen L., Holmegaard S.N., Transbol I. Mouridsen H.T. (1994) Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study. Journal of Clinical Oncology 12, 992 997.
28. Lind M., Vernon C., Cruickshank D., Wilkinson P., Littlewood T., Stuart N., Jenkinson C., Grey-Amante P., Doll H. Wild D. (2002) The level of haemoglobin in anaemic cancer patients correlates positively with quality of life. British Journal of Cancer 86, 1243 1249.
29. Loibl S., Schwedler K., Von Minckwitz G., Strohmeier R., Mehta K.M. Kaufmann M. (2007) Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patients - a double-blind, randomized study. Annals of Oncology 18, 689 693.
30. Love R.R., Cameron L., Connell B.L. Leventhal H. (1991) Symptoms associated with tamoxifen treatment in postmenopausal women. Archives of Internal Medicine 151, 1842 1847.
31. Mortimer J.E., Boucher L., Baty J., Knapp D.L., Ryan E. Rowland J.H. (1999) Effect of tamoxifen on sexual functioning in patients with breast cancer. Journal of Clinical Oncology 17, 1488 1492.
32. Nayfield S.G. Gorin M.B. (1996) Tamoxifen-associated eye disease. A review. Journal of Clinical Oncology 14, 1018 1026.
33. Ramaswamy B. Shapiro C.L. (2003) Osteopenia and osteoporosis in women with breast cancer. Seminars in Oncology 30, 763 775.
34. Schipper H., Clinch J., Mcmurray A. Levitt M. (1984) Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation. Journal of Clinical Oncology 2, 472 483.
35. Schover L.R. (1994) Sexuality and body image in younger women with breast cancer. Journal of the National Cancer Institute. Monographs 16, 177 182.
36. Wasan K.M., Goss P.E., Pritchard P.H., Shepherd L., Palmer M.J., Liu S., Tu D., Ingle J.N., Heath M., Deangelis D. Perez E.A. (2005) The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). Annals of Oncology 16, 707 715.